Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Colorcon
McKinsey
Medtronic
McKesson

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

INREBIC Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Inrebic, and when can generic versions of Inrebic launch?

Inrebic is a drug marketed by Impact and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-six patent family members in thirty-three countries.

The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.

Summary for INREBIC
International Patents:76
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 78
Patent Applications: 52
Drug Prices: Drug price information for INREBIC
DailyMed Link:INREBIC at DailyMed
Drug patent expirations by year for INREBIC
Drug Prices for INREBIC

See drug prices for INREBIC

Generic Entry Opportunity Date for INREBIC
Generic Entry Date for INREBIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for INREBIC
091D268
2TA
3-methyl-5-(2-morpholinoethyl)-6,7-dehydro-1H-pyrrolo[3,2-c]pyridine-4(5H)-one
6L1XP550I6
936091-26-8
936091-26-8 pound not TG101348 pound not TG 101348
945381-69-1
A25534
AB1008513
ABP000705
AC-30260
AK-50248
AKOS015842621
AN-4247
AOB2041
AS-16248
BC644857
BCP02300
BDBM50332294
Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-
BRD-K12502280-001-01-5
C27H36N6O3S
cc-67
CHEBI:91408
CHEMBL1287853
CS-0052
D10630
DA-40258
DA-45538
DB12500
DTXSID90239483
EX-5961
EX-A170
Fedratinib
Fedratinib (SAR302503, TG101348)
Fedratinib (USAN/INN)
Fedratinib [USAN:INN]
Fedratinib TG101348
Fedratinib-SAR302503-TG101348
Fedratinib|||N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-benzenesulfonamide
FT-0705969
FT-0763396
FT-0766818
GTPL5716
HMS3656L19
HMS3744G17
HY-10409
J-523769
KIN0000251
MFCD12922515
MLS006011155
N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyr
n-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino
N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide
N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide
N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)-benzenesulfonamide
N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide
N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide
NCGC00244252-01
NCGC00244252-07
RS0112
s2736
SAR 302503
SAR-302503
SAR302503
SAR302503 (TG-101348)
SB14604
SC-86405
SCHEMBL263741
SMR004702929
SW218187-2
SYN1104
TG 101348
Tg-101348
TG101348
TG101348 (SAR302503)
TG101348 HCl
TG101348(Fedratinib)
TG101348/TG-101348/
UNII-6L1XP550I6
W-5547
Y0268
ZINC19862646

US Patents and Regulatory Information for INREBIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impact INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327-001 Aug 16, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Impact INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327-001 Aug 16, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Impact INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327-001 Aug 16, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Medtronic
Dow
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.